ASTH
Astrana Health Inc
$
25.535
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
31.000
Open
31.000
VWAP
27.81
Vol
1.20M
Mkt Cap
1.26B
Low
25.535
Amount
33.49M
EV/EBITDA(TTM)
13.12
Total Shares
49.38M
EV
1.63B
EV/OCF(TTM)
15.27
P/S(TTM)
0.40
Astrana Health, Inc. is a physician-centric, artificial intelligence (AI)-powered healthcare company focused on delivering patient-centered care. The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company's segments include Care Partners, Care Delivery, and Care Enablement. Its Care Partners segment is focused on building and managing provider networks by partnering with, empowering, and investing in provider partners aligned on a shared vision for coordinated care delivery. Its Care Delivery organization includes primary care, multi-specialty care, and ancillary care services. Its Care Enablement segment represents a comprehensive platform that integrates clinical, operational, financial, and administrative information. It supports more than 20,000 providers.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
941.84M
+43.83%
0.440
+131.58%
891.18M
+43.65%
0.427
+205.36%
953.88M
+43.4%
0.424
-382.86%
Estimates Revision
The market is revising Upward the revenue expectations for Astrana Health, Inc. (ASTH) for FY2025, with the revenue forecasts being adjusted by 0.25% over the past three months. During the same period, the stock price has changed by -11.00%.
Revenue Estimates for FY2025
Revise Upward
+0.25%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+2.67%
In Past 3 Month
Stock Price
Go Down
-11.00%
In Past 3 Month
7 Analyst Rating
Wall Street analysts forecast ASTH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASTH is 43.50 USD with a low forecast of 36.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 25.535
Low
36.00
Averages
43.50
High
50.00
Current: 25.535
Low
36.00
Averages
43.50
High
50.00
BTIG
David Larsen
Buy
downgrade
$70 -> $50
2025-07-30
Reason
BTIG
David Larsen
Price Target
$70 -> $50
2025-07-30
downgrade
Buy
Reason
BTIG analyst David Larsen lowered the firm's price target on Astrana Health to $50 from $70 and keeps a Buy rating on the shares. The company could face headwinds from higher cost trends, though it has already provided favorable comments around Q2 results, the analyst tells investors in a research note. There have been some worries about home-health reimbursement, but the specialty medical trend and home-health and rehab volumes will likely far offset these worries, the firm added.
Barclays
Andrew Mok
Hold
Initiates
$36
2025-04-01
Reason
Barclays
Andrew Mok
Price Target
$36
2025-04-01
Initiates
Hold
Reason
Barclays initiated coverage of Astrana Health with an Equal Weight rating and $36 price target. The company is well positioned to capture improving rates in the government sector, but the scale and complexity of the pending Prospect deal tempers excitement, the analyst tells investors in a research note. The firm believes the near-term execution risks are real given the scale. As such, it comes out on the sidelines.
Truist Securities
Jailendra Singh
Strong Buy
Maintains
$50 → $46
2025-03-18
Reason
Truist Securities
Jailendra Singh
Price Target
$50 → $46
2025-03-18
Maintains
Strong Buy
Reason
Truist analyst Jailendra Singh lowered the firm's price target on Astrana Health to $46 from $50 and keeps a Buy rating on the shares. The firm is updating its model to reflect the company's Q4 earnings release and 2025 outlook, the analyst tells investors in a research note. Truist adds that its valuation represents a slight premium to Astrana's next-12-months enterprise value to EBITDA average multiple over the last year and gives credit to its recent history of outperformance relative to the value-based care industry as a whole.
B of A Securities
Adam Ron
Strong Buy
Maintains
$55 → $49
2025-03-04
Reason
B of A Securities
Adam Ron
Price Target
$55 → $49
2025-03-04
Maintains
Strong Buy
Reason
Baird
Michael Ha
Buy
Maintains
$86 → $50
2025-03-03
Reason
Baird
Michael Ha
Price Target
$86 → $50
2025-03-03
Maintains
Buy
Reason
Baird lowered the firm's price target on Astrana Health to $50 from $86 and keeps an Outperform rating on the shares.
Stifel
Craig Jones
Strong Buy
Maintains
$70 → $56
2025-02-20
Reason
Stifel
Craig Jones
Price Target
$70 → $56
2025-02-20
Maintains
Strong Buy
Reason
Stifel lowered the firm's price target on Astrana Health to $56 from $70 and keeps a Buy rating on the shares ahead of Astrana reporting Q4 earnings on Thursday, February 27. The firm expects the call to be focused on integration of CHS and close of Prospect Health, 2025 guidance and medical cost trends, and progress in transitioning to full-risk, the analyst tells investors in a preview.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Astrana Health Inc (ASTH.O) is 14.49, compared to its 5-year average forward P/E of 36.78. For a more detailed relative valuation and DCF analysis to assess Astrana Health Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Undervalued
5Y Average PE
36.78
Current PE
14.49
Overvalued PE
56.40
Undervalued PE
17.17
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Fair
5Y Average EV/EBITDA
11.71
Current EV/EBITDA
6.34
Overvalued EV/EBITDA
18.08
Undervalued EV/EBITDA
5.34
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
1.62
Current PS
25.54
Overvalued PS
4.57
Undervalued PS
-1.33
Financials
Annual
Quarterly
FY2025Q3
YoY :
+99.71%
956.05M
Total Revenue
FY2025Q3
YoY :
+57.99%
44.91M
Operating Profit
FY2025Q3
YoY :
-94.33%
1.08M
Net Income after Tax
FY2025Q3
YoY :
-96.97%
0.01
EPS - Diluted
FY2025Q3
YoY :
-76.63%
7.40M
Free Cash Flow
FY2025Q3
YoY :
-38.32%
8.53
Gross Profit Margin - %
FY2025Q3
YoY :
-17.49%
3.35
FCF Margin - %
FY2025Q3
YoY :
-97.23%
0.11
Net Margin - %
FY2025Q3
YoY :
-74.79%
2.37
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
175.0K
USD
1
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
175.0K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ASTH News & Events
Events Timeline
2025-11-06 (ET)
2025-11-06
16:26:22
Astrana Health Adjusts 2025 Revenue Forecast to $2.5B-$2.7B, Down from $3.1B-$3.18B
2025-11-06
16:25:21
Astrana Health announces Q3 EPS of 1 cent compared to 33 cents in the previous year.
2025-08-07 (ET)
2025-08-07
16:49:57
Astrana Health sees 2025 revenue $3.1B-$3.3B, consensus $3.18B
Sign Up For More Events
Sign Up For More Events
News
2.0
11-07NASDAQ.COMASTH Experiences Significant Drop Below Key Moving Average
9.5
11-06PRnewswireAstrana Health, Inc. Reports Third Quarter 2025 Results
7.5
09-15MarketWatch11 Rapidly Expanding Small-Cap Stocks That May Benefit from the Fed's Upcoming Decision
Sign Up For More News
People Also Watch
LION
Lionsgate Studios Corp
6.870
USD
-2.28%
OMCL
Omnicell Inc
35.680
USD
-0.22%
COCO
Vita Coco Company Inc
42.110
USD
+0.69%
DBRG
DigitalBridge Group Inc
10.540
USD
-3.66%
TALO
Talos Energy Inc
10.380
USD
+6.13%
TGS
Transportadora de Gas del Sur SA
28.630
USD
-2.05%
VITL
Vital Farms Inc
34.680
USD
-2.25%
BEAM
Beam Therapeutics Inc
22.210
USD
-4.06%
HLMN
Hillman Solutions Corp
8.760
USD
+0.46%
FAQ
What is Astrana Health Inc (ASTH) stock price today?
The current price of ASTH is 25.535 USD — it has decreased -23.46 % in the last trading day.
What is Astrana Health Inc (ASTH)'s business?
What is the price predicton of ASTH Stock?
What is Astrana Health Inc (ASTH)'s revenue for the last quarter?
What is Astrana Health Inc (ASTH)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Astrana Health Inc (ASTH)'s fundamentals?
How many employees does Astrana Health Inc (ASTH). have?